Idioma:

Statin use and risk of liver cancer: Evidence from two population‐based studies

Tran, Kim Tu ; McMenamin, Úna C. ; Coleman, Helen G. ; Cardwell, Chris R. ; Murchie, Peter ; Iversen, Lisa ; Lee, Amanda J. ; Thrift, Aaron P.

International journal of cancer, 2020-03, Vol.146 (5), p.1250-1260 [Periódico revisado por pares]

Hoboken, USA: John Wiley & Sons, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Statin use and risk of liver cancer: Evidence from two population‐based studies
Autor: Tran, Kim Tu ; McMenamin, Úna C. ; Coleman, Helen G. ; Cardwell, Chris R. ; Murchie, Peter ; Iversen, Lisa ; Lee, Amanda J. ; Thrift, Aaron P.
Assuntos: Aged ; Bile ducts ; Biobanks ; Cancer ; Case-Control Studies ; Cholesterol ; Cohort Studies ; Epidemiology ; Female ; Health risk assessment ; Health risks ; Hepatocellular carcinoma ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; Informatics ; intrahepatic bile duct carcinoma ; Liver ; Liver cancer ; Liver diseases ; Liver Neoplasms - epidemiology ; Logistic Models ; Male ; Medical research ; Middle Aged ; Population studies ; Population-based studies ; Prospective Studies ; Risk ; Statins ; United Kingdom - epidemiology
É parte de: International journal of cancer, 2020-03, Vol.146 (5), p.1250-1260
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Epidemiological studies of statin use and liver cancer risk have produced conflicting results. We examined the association between statin use and risk of primary liver cancer in two large independent study populations taking account of important covariates and main indications of statins such as high cholesterol and chronic liver disease. We performed a nested case–control study within the Scottish Primary Care Clinical Informatics Unit (PCCIU) database. Five controls were matched to cases with primary liver cancer and we used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations with statin use. We also conducted a prospective cohort study within the UK Biobank using self‐reported statin use and cancer‐registry recorded primary liver cancer outcomes. Cox regression was used to calculate hazard ratios (HRs) and 95% CIs. In the PCCIU case–control analysis, 434 liver cancer cases were matched to 2,103 controls. In the UK Biobank cohort, 182 out of 475,768 participants developed incident liver cancer. Statin use was associated with 39% lower risk of liver cancer in the PCCIU (adjusted OR 0.61, 95% CI 0.43–0.87). When we examined specific subtypes of liver cancer in the UK Biobank, statin use was associated with lower risk of hepatocellular carcinoma (HCC; adjusted HR, 0.48; 95% CI, 0.24–0.94) but not intrahepatic bile duct carcinoma (IBDC; adjusted HR, 1.09; 95% CI, 0.45–2.64). In conclusion, we found a consistent inverse relationship between statin use and risk of primary liver cancer which was only seen for HCC but not IBDC. What's new? Does statin use affect the risk of liver cancer? Previous studies have been contradictory, perhaps due to their failure to adjust for covariates such as high cholesterol and chronic liver disease. In this analysis of two large, independent studies, the authors found that the risk of hepatocellular carcinoma was cut by almost half with statin use. The same did not hold true for intrahepatic bile duct carcinoma. With liver‐cancer incidence and mortality rising worldwide, these results may offer one avenue for improved prevention.
Editor: Hoboken, USA: John Wiley & Sons, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Statin use and risk of liver cancer: Evidence from two population‐based studies

Tran, Kim Tu ; McMenamin, Úna C. ; Coleman, Helen G. ; Cardwell, Chris R. ; Murchie, Peter ; Iversen, Lisa ; Lee, Amanda J. ; Thrift, Aaron P.

Hoboken, USA: John Wiley & Sons, Inc

Buscando em bases de dados remotas. Favor aguardar.